Publications

USPTO Issues Notice of Allowance for SPV374

Corporate announcement

U.S. Patent Application No. 17/416,971 was allowed for SPV374 compound structures and composition-of-matter claims, securing American IP exclusivity through 2040+.

SPV Therapeutics Strengthens Oncology IP Portfolio with U.S. Patent Grant

U.S. Patent No. 12,760,023 B2, granted October 13, 2026, covers a differentiated bicyclo[1.1.1]pentane (BCP)-based CDK inhibitor chemotype, complementing SPV’s CDK4/6/9 inhibitor strategy and SPV113 backup program.